Deerfield Management NRIX Position
Exited9-Fund ConvergenceDeerfield Management exited their position in Nurix Therapeutics Inc. (NRIX) in Q3 2024, after holding the stock for 4 quarters.
The position was first reported in Q4 2023 and has been tracked across 4 quarterly 13F filings.
NRIX is a convergence signal: 9 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for NX-5948 in 655 days (Jan 31, 2028), making the timing of Deerfield's position particularly relevant.
Short interest stands at 17.7% of float with 19.3 days to cover, indicating significant bearish positioning against the stock.
About Nurix Therapeutics Inc.
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.
Full company profile →Short Interest
17.7%
19.3 days to cover
Deerfield Management NRIX Position History
Frequently Asked Questions
Does Deerfield Management own NRIX?
No. Deerfield Management exited their position in Nurix Therapeutics Inc. (NRIX) in Q3 2024. They previously held the stock for 4 quarters.
How many hedge funds own NRIX?
9 specialist biotech hedge funds currently hold NRIX, including Redmile Group, Deep Track Capital, Baker Bros. Advisors and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy NRIX?
Deerfield Management's position in NRIX was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's NRIX position increasing or decreasing?
Deerfield Management completely exited their NRIX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NRIXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →